[1] |
Mohammed MA, Moles RJ, Chen TF. Medication-related burden and patients’ lived experience with medicine:a systematic review and metasynthesis of qualitative studies[J]. BMJ Open, 2016, 6(2):e010035.
|
[2] |
Read J, Williams J. Positive and negative effects of antipsychotic medication:an international online survey of 832 recipients[J]. Curr Drug Saf, 2019, 14(3):173-181.
|
[3] |
McCutcheon RA. Disentangling relapse and adherence in psychosis[J]. Lancet Psychiatry, 2020, 7(9):722-723.
DOI
PMID
|
[4] |
Zeithaml VA. Consumer perceptions of price,quality,and value:a means-end model and synthesis of evidence[J]. J Mark, 1988, 52(3):2.
|
[5] |
Martin A, Bessonova L, Hughes R, et al. Systematic review of real-world treatment patterns of oral antipsychotics and associated economic burden in patients with schizophrenia in the United States[J]. Adv Ther, 2022, 39(9):3933-3956.
DOI
PMID
|
[6] |
Kretchy IA, Appiah B, Agyabeng K, et al. Psychotropic medicine beliefs,side effects and adherence in schizophrenia:a patient-caregiver dyad perspective[J]. Int J Clin Pharm, 2021, 43(5):1370-1380.
|
[7] |
Teetharatkul T, Vitayanont A, Liabsuetrakul T, et al. Associations between symptom severity and well-being among Thai patients with schizophrenia:a cross-sectional analytical study[J]. BMC Psychiatry, 2021, 21(1):348.
DOI
PMID
|
[8] |
范肖冬. ICD-10精神与行为障碍分类[M]. 北京: 人民卫生出版社,1993:72-89.
|
|
Fan XD. ICD-10 classification of mental and behavioral disorders[M]. Beijing: People’s Medical Publishing House,1993:72-89.
|
[9] |
Wang WL, Zhou YQ, Chai NN, et al. Mediation and moderation analyses:exploring the complex pathways between hope and quality of life among patients with schizophrenia[J]. BMC Psychiatry, 2020, 20(1):22.
|
[10] |
郭汲源, 赵祖安, 哈斯, 等. 抗精神病药治疗中主观舒适度(SWN)简表中文译本的信度和效度测试报告[J]. 中国民康医学, 2003, 15(12):705-707.
|
|
Guo JY, Zhao ZA, Ha S, et al. Testing the reliability and validity of Chinese Version of Subjective Well-being under Neuroleptics(SWN) Short Form[J]. Med J Chin People Heacth, 2003, 15(12):705-707.
|
[11] |
Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs[J]. Schizophre Res, 2001, 50(1-2):79-88.
|
[12] |
Krska J, Morecroft CW, Rowe PH, et al. Measuring the impact of long-term medicines use from the patient perspective[J]. Int J Clin Pharm, 2014, 36(4):675-678.
|
[13] |
王永利, 张振香, 林蓓蕾, 等. 用药生活问卷的汉化及其在社区老年多重用药患者中的信效度分析[J]. 中国全科医学, 2020, 23(15):1864-1872.
DOI
|
|
Wang YL, Zhang ZX, Lin BL, et al. Development, validity and reliability of the Chinese Version of Living with Medicines Questionnaire in community living elderly patients with polypharmacy:a cross-cultural adaptation[J]. Chin Gen Pract, 2020, 23(15):1864-1872.
|
[14] |
Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire(BMQ):the development and evaluation of a new method for assessing the cognitive representation of medication[J]. Psychology and Health, 1999,14:1-24.
|
[15] |
吕扬, 李峥, 韩美英, 等. 服药信念量表中文版在老年抑郁症患者中的信效度研究[J]. 中华护理杂志, 2014, 49(4):389-393.
|
|
Lü Y, Li Z, Han MY, et al. The reliability and validity of the Chinese version of Beliefs about Medical Questionnaire among elderly patients with depressive disorder[J]. Chin J Nurs, 2014, 49(4):389-393.
|
[16] |
Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syn-drome Scale(PANSS) for schizophrenia[J]. Schizophrenia Bull, 1987, 13(2):261-276.
|
[17] |
司天梅, 杨建中, 舒良, 等. 阳性和阴性症状量表(PANSS,中文版)的信、效度研究[J]. 中国心理卫生杂志, 2004, 18(1):45-47.
|
|
Si TM, Yang JZ, Shu L, et al. The reliability,validity of PANSS and its implication[J]. Chin Ment Health J, 2004, 18(1):45-47.
|
[18] |
Amro I, Ghuloum S, Hammoudeh S, et al. Thematic analysis of the raters’ experiences administering scales to assess depression and suicide in Arab schizophrenia patients[J]. BMC Psychiatry, 2022, 22(1):652.
|
[19] |
Schneider-Thoma J, Chalkou K, Dörries C, et al. Comparative effcacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia:a systematic review and network metaanalysis[J]. Lancet, 2022,399:824-836.
|
[20] |
Bogers JPAM, Hambarian G, Walburgh Schmidt N, et al. Risk factors for psychotic relapse after dose reduction or discon-tinuation of antipsychotics in patients with chronic schizo-phrenia:a meta-analysis of randomized controlled trials[J]. Schizophr Bull, 2023, 49(1):11-23.
|
[21] |
Dai X, Gao M, Liu Y, et al. Analysis of inpatient cost burden and influencing factors of seniors’ patients with mental illness in Dalian,China[J]. BMC Geriatr, 2023, 23(1):739.
|
[22] |
Stürup AE, Hjorthøj C, Jensen HD, et al. Self-reported reasons for discontinuation or continuation of antipsychotic medication in individuals with first-episode schizophrenia[J]. Early Interv Psychia, 2023, 17(10):974-983.
|
[23] |
牛雨昕, 郭永攀, 张春慧, 等. 慢性病共病患者用药体验的Meta整合[J]. 中华护理杂志, 2023, 58(22):2777-2784.
DOI
URL
|
|
Niu YX, Guo YP, Zhang CH, et al. Medication experiences of patients with chronic multimorbidities:a qualitative Meta-synthesis[J]. Chin J Nurs, 2023, 58(22):2777-2784.
|
[24] |
吴韬, 方媛媛, 钱瑞莲. 共享决策在严重精神障碍患者中的应用进展[J]. 中华护理杂志, 2022, 57(18):2205-2211.
|
|
Wu T, Fang YY, Qian RL. Application progress of shared decision-making for patients with severe mental disorders[J]. Chin J Nurs, 2022, 57(18):2205-2211.
|